Kamada Ltd. (KMDA)

Market Cap	387.34M
Revenue (ttm)	160.95M
Net Income (ttm)	14.46M
Shares Out	57.51M
EPS (ttm)	0.25
PE Ratio	26.78
Forward PE	22.54
Dividend	$0.20 (2.95%)
Ex-Dividend Date	Mar 17, 2025

Volume	49,513
Open	6.84
Previous Close	6.83
Day's Range	6.68 - 6.77
52-Week Range	4.74 - 9.15
Beta	0.21
Analysts	Strong Buy
Price Target	14.67 (+117.33%)
Earnings Date	Mar 5, 2025

About KMDA

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM f...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1990
• Employees: 420
• Stock Exchange: NASDAQ
• Ticker Symbol: KMDA
• Website: https://www.kamada.com

Financial Performance

In 2024, Kamada's revenue was $160.95 million, an increase of 12.93% compared to the previous year's $142.52 million. Earnings were $14.46 million, an increase of 74.58%.

Analyst Forecast

According to 3 analysts, the average rating for KMDA stock is "Strong Buy." The 12-month stock price forecast is $14.67, which is an increase of 117.33% from the latest price.

Price Target

$14.67

(117.33% upside)

Analyst Consensus: Strong Buy